Objective:Quality of life (QOL) in cancer patients can be influenced by the presence of medical conditions, such as oral mucositis (OM). There is still limited knowledge about this issue among patients in Jordan, and this could be related to the absence of research instruments testing QOL among cancer patients with OM. This study measured the QOL among cancer patients using the Functional Assessment of Cancer Therapy-General (FACT-G), Arabic version.Methods:This was a cross-sectional study on 118 head-and/or-neck cancer patients with OM in Jordan. Data were submitted to measures of normality, reliability, and validity using exploratory factor analysis. The study also measured QOL among the study sample.Results:FACT-G demonstrated good internal consistency reliability and validity. Factor analysis indicated the presence of four factors explained by 24 items representing a valid FACT-G, Arabic version. Scores reflected low QOL compared to reported normative values in the literature. The values used to compare findings from this study were extracted from international literature; no similar values were present in published literature.Conclusions:FACT-G, Arabic version, is valid and reliable when applied to this study population. Further testing is recommended, which would include the establishment of normative values.

A 68 years old female, was diagnosed as a case of right breast cancer in 2013; grade II/III according to Bloom Richardson grading, Modify radical mastectomy (MRM) was done and the pathology report showed moderately differentiated invasive ductal carcinoma (IDC), stage T3N3M0. Immunohisrochemisty (IHC) findings revealed a tumor with Triple positive. Patient refused to treat by chemotherapy. Patient was given adjuvant trastuzumab (first dose 8 mg/kg, followed by 6 mg/kg every three weeks) for the period of one year (16) cycles after which she went on regular follow up. Exemestane tab for 5 years and radiotherapy (50 gray in 25 fractions) was applying on right breast. One year and half after diagnosed primary breast cancer, patient complained from severe diarrhea 8 times per day watery contents, vomiting and suffered from lower abdominal pain. PET scan for whole body in October 2014 was done; the results showed ascending colon is highly suspicious for malignancy and moderately hypermetabolic left adrenal mass. Subtotal colectomy surgery was done, the pathology report of biopsy revealed low grade malignant neuroendocrine neoplastic lesion stage of T3N1Mo. Physician prescribed octreotide acetate 20 mg I. M monthly due to neuroendocrine lesion. In January 2016, cancer recurrence in the same right breast, IHC revealed ER+, PR−, Her 2+, physician decided to change exemestane to fulvestrant 250 mg s. c for 6 cycles. Radiation therapy was applied 20 gray in 10 fractions on scar. In May 2016, CAP-CT scan result revealed two enlarged left axillary L.N and left soft tissue density adrenal mass (3.0 × 2.3).

Background: Bone metastasis with advance cancer stage forms approximately 85% of all cases. Breast cancer patients frequently suffer from bone pain, functional impairment due to bone metastasis which impacts negatively on their quality of life. Subjects and Methods: A retrospective study of breast cancer patients who have bone metastasis at diagnosis or developing bone metastasis during 5 years from breast cancer diagnosis (2011)(2012)(2013)(2014)(2015)(2016) and who received zometa 4 mg monthly in radiotherapy department was included and conducted in 2017. We reviewed 107 female with breast cancer diagnosed by bone scan and/or PET scan as cases of bone metastasis enrolled. Questionnaire was designed to document all variables besides, demographic data which contain (age, histopathology reading invasive ductal carcinoma, invasive lobular carcinoma or others, ER status, PR status, Her2neu status and lymph node status & stage, Onset of metastasis, Menopausal Status & finally No. of metastasis site). Results: We noticed that the highest percentage of patients diagnosed as bone metastasis were 45 years and more, and 86% of them were invasive ductal carcinoma; regarding hormonal status we noticed that ER, PR status was positive in 90.7% and 82.2% of cases respectively, Her2neu receptors were amplified in 26.2% of them, positive lymph nodes were seen positive in 80.4% of cases and 31.8% of them were shown (N3) stage; we noticed that the only risk factor of bone metastasis is PR+ significantly associated with lesions multiplicity (0.049). There is no significant association between ER, PR, Her2neu, lymph nodes and menopausal status and onset of bone metastasis, also age, ER, Her2neu, lymph nodes and menopausal status are not associated significantly with No. of metastatic lesions. Conclusion: PR+ is significantly associated with lesions multiplicity (0.049), which is considered as a risk factor of bone metastasis in our study.

Objective:a. To compare the effectiveness of tamoxifin and megestrol acetate drug on metastasis and recurrence low grade endometrial stromal sarcoma (LGESS). b. To identify the interval between the first presentation of LGESS and the recurrence of (LGESS).Methods: This is a rare case report of A 45-year-old woman with (LG-ESS), patients' history was collected by the authors ourselves through a structured interview, data was obtained from the patient's file including radiological pictures, pathological reports and drug doses. using PubMed data base for discussion this case. This woman with a history of hysteracomy and bilateral salpingooopharectomy 15 year earlier was admitted to Al Basheer hospital in 2015, presented with left breast mass, biopsy revealed (LGESS). CT scan have shown multiple breast and lung nodules. Doctor prescribed tamoxifen tab 20 mg once daily. After three months of follow up, the size of the metastatic nodules was increased, new umbilical mass and left hemipelvic mass were discovered. Then, megestrol acetate oral suspension had been prescribed 160mg daily. After 6 months of follow up the patient shown good response to treatment; the size of metastatic lungs and breast nodules were decreased, Umbilical and left hemipelvic lesions were decrease, but new small focal liver lesion was seen.Results: patient LG-ESS progression with tamoxifen by increasing the size of all nodules, but good response with megestrol acetate by decreasing the size of nodules. The disease was metastatic after 15 years old from first presentation. Conclusion:Megestrol acetate was effective treatment rather than tamoxefin in metastatic case, so administration of megestrol acetate is recommended for metastasis and recurrence (LG-ESS). Highlights:a. Megestrol acetate was considered as effective hormonal therapy for LGSS recurrence, metastasis and non resectable by tumor size regression. b. Tamoxifen was showed ineffective evidence by tumor size progression.

No abstract